07.08.2013 • NewsLanxessQ2 2013Q2 results

Lanxess Sees Weak 2013

After announcing a weak first half of 2013, Germany's Lanxess said it doesn't expect to see an improvement in business conditions in the second half of the year. The company attributed this in part to customers destocking inventories, particularly in Asia, as well as to a weak consumer sentiment overall. As a result, the company has lowered its May outlook of €1 billion expected EBITDA pre exceptionals to €700-800 million, excluding potential inventory devaluations.

Meanwhile, it maintained its mid-term target of €1.8 billion euros EBITDA pre exceptionals in 2018 despite the difficult conditions.

"The first half of 2013 does not meet our own high standards," Lanxess CEO Axel Heitman said. "Trading conditions for our businesses remain tough and the fragile sentiment in Europe is now evident in other markets that are important for us, such as China and Brazil."

For the second quarter, net income declined 95% to €9 million from €174 million in the prior year.
EBITDA before exceptionals declined 45% year-over-year to €198 million. Adjusted EBITDA margin fell to 9.2% from 14.9% last year.

Sales were down 11.7% to €2.14 billion from €2.42 billion a year ago, due to a strong decrease in selling prices triggered mainly by a decline in raw material prices, which impacted the company's Performance Polymers segment. The continuing weak demand in the automotive and tire industries also affected the sales development. This was partly offset by demand for agrochemicals, especially in Europe, which remained positive and contributed to the solid development of the Advanced Intermediates segment.

 

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read